Share information
286.20 €
+1.27 %
05/11/2026 12:39
+1.27 %
Open
High
Low
Volume
282.60 €
288.70 €
282.40 €
27,017
Latest News
04-Nov-2026
UCB advances its digital antibody engineering program with new Cradle collaboration
22-Oct-2026
Strong Performance Drives Further Upgrade to UCB’s 2026 Financial Guidance
19-Oct-2026
Transparency notification Wellington
16-Oct-2026
UCB announces U.S. FDA approval for ZILBRYSQ[®] (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis